Clinical Trial

Predicting Cancer Risk With Digital and Molecular Markers

Study acronym: PräDigt
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 8, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to identify new markers to predict the risk of developing cancer, primarily breast cancer. For this purpose, researchers will compare data obtained from cancer patients and healthy individuals. If characteristic differences are identified, e.g. in biomarkers, life style or family history, this may indicate a person's increased risk of developing cancer.
Trial Details
NCT Number NCT06962670
Lead Sponsor University of Erlangen-Nürnberg Medical School
Conditions Breast Cancer, Lung Cancer, Colorectal Cancer, Gynecologic Cancer
Enrollment 1,250 participants
Start Date 2024-09-14
Primary Completion 2025-09 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-08